Campbell & CO Investment Adviser LLC Has $741,000 Position in Alkermes plc $ALKS

Campbell & CO Investment Adviser LLC lessened its stake in Alkermes plc (NASDAQ:ALKS) by 56.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,691 shares of the company’s stock after selling 31,808 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Alkermes were worth $741,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Norges Bank bought a new stake in Alkermes in the second quarter valued at approximately $53,326,000. BNP Paribas Financial Markets lifted its position in shares of Alkermes by 787.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,135,478 shares of the company’s stock worth $32,486,000 after purchasing an additional 1,007,488 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Alkermes in the 3rd quarter valued at $27,040,000. Holocene Advisors LP boosted its stake in shares of Alkermes by 31.2% in the 2nd quarter. Holocene Advisors LP now owns 2,853,768 shares of the company’s stock valued at $81,646,000 after purchasing an additional 679,166 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Alkermes by 43.0% during the second quarter. Bank of America Corp DE now owns 2,155,087 shares of the company’s stock worth $61,657,000 after buying an additional 647,905 shares during the period. 95.21% of the stock is currently owned by institutional investors.

Insider Transactions at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 5,000 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the sale, the executive vice president owned 61,740 shares in the company, valued at approximately $1,852,200. The trade was a 7.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 25,748 shares of company stock valued at $765,060. Company insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ALKS shares. Jefferies Financial Group set a $56.00 target price on shares of Alkermes and gave the company a “buy” rating in a report on Tuesday, October 28th. Mizuho lifted their price objective on Alkermes from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 27th. Deutsche Bank Aktiengesellschaft dropped their price objective on Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Needham & Company LLC raised their target price on Alkermes from $43.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen downgraded Alkermes from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.69.

Alkermes Price Performance

Shares of ALKS opened at $31.75 on Wednesday. Alkermes plc has a one year low of $25.17 and a one year high of $36.45. The company has a market cap of $5.24 billion, a PE ratio of 15.72 and a beta of 0.48. The stock has a 50-day moving average of $29.12 and a 200-day moving average of $29.15.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.08. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The business had revenue of $394.19 million for the quarter, compared to analyst estimates of $355.23 million. During the same quarter in the prior year, the company earned $0.73 earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. Analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.